Comparison of NanoString Technologies Inc. (NSTG) and Cue Biopharma Inc. (NASDAQ:CUE)

NanoString Technologies Inc. (NASDAQ:NSTG) and Cue Biopharma Inc. (NASDAQ:CUE), both competing one another are Biotechnology companies. We will compare their dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
NanoString Technologies Inc. 24 0.00 33.04M -2.74 0.00
Cue Biopharma Inc. 9 0.00 17.57M -2.11 0.00

Table 1 highlights NanoString Technologies Inc. and Cue Biopharma Inc.’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 demonstrates the net margins, return on equity and return on assets of NanoString Technologies Inc. and Cue Biopharma Inc.

Net Margins Return on Equity Return on Assets
NanoString Technologies Inc. 139,233,038.35% -166.7% -51.1%
Cue Biopharma Inc. 194,143,646.41% 0% 0%

Liquidity

The current Quick Ratio of NanoString Technologies Inc. is 4.5 while its Current Ratio is 4.8. Meanwhile, Cue Biopharma Inc. has a Current Ratio of 3 while its Quick Ratio is 3. NanoString Technologies Inc. is better positioned to pay off its short-term and long-term debts than Cue Biopharma Inc.

Analyst Ratings

The table delivered features the ratings and recommendations for NanoString Technologies Inc. and Cue Biopharma Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
NanoString Technologies Inc. 0 0 1 3.00
Cue Biopharma Inc. 0 0 0 0.00

NanoString Technologies Inc.’s upside potential is 4.95% at a $28 average price target.

Institutional and Insider Ownership

Roughly 90.3% of NanoString Technologies Inc. shares are owned by institutional investors while 21.7% of Cue Biopharma Inc. are owned by institutional investors. Insiders owned roughly 0.4% of NanoString Technologies Inc.’s shares. Insiders Competitively, owned 0.4% of Cue Biopharma Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
NanoString Technologies Inc. 2.14% 11.92% 26.53% 51.22% 189.26% 121.58%
Cue Biopharma Inc. 19.74% -6.1% 3.36% 65.54% -11.97% 76.81%

For the past year NanoString Technologies Inc.’s stock price has bigger growth than Cue Biopharma Inc.

NanoString Technologies, Inc. develops, manufactures, and sells life science tools for translational research and molecular diagnostic products worldwide. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter MAX and FLEX systems that include nCounter Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples through the images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; and Pan Cancer pathways gene expression panels, including pathways, immune profiling, and progression panels, as well as nCounter Vantage 3D, other gene expression, miRNA expression, and cancer copy number variation panels. Further, the company offers nCounter Elements reagents that allow users to design customized assays for gene expression, copy number variation, and gene fusions; Master Kits, which include ancillary reagents and plasticware to setup and process samples in the nCounter Prep Station and nCounter Digital Analyzer; and nCounter Dx Analysis System and Prosigna molecular diagnostic test kits. It markets its systems and related consumables to researchers in academic, government, and biopharmaceutical laboratories, as well as to clinical laboratories and medical centers. NanoString Technologies, Inc. has collaboration with Celgene Corporation; Merck Sharp & Dohme Corp.; Medivation, Inc.; and Astellas Pharma, Inc. The company was founded in 2003 and is headquartered in Seattle, Washington.

Cue Biopharma, Inc., a preclinical stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat various cancers and autoimmune disorders. Its lead drug candidate comprises CUE-101, a variant form of the cytokine Interleukin-2 and a T cell antigen to target and activate T cells specific to HPV-related cancers. The company's biologics drug candidates also include CUE-100 series to improve various tumor specific T cells; and CUE-200 series to reinvigorate exhausted T cells. It also offers MOD costimulatory optimization and discovery platform and viraTope T cell epitope discovery platform to develop novel biologics for addressing new indications in oncology and autoimmune disorders. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.